APA (7th ed.) Citation

M, H., LM, d. L., OM, G., S, B., AC, V., M, D., . . . NA, S. (2015). RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell Carcinoma. Molecular cancer therapeutics, 14(8), 1939. https://doi.org/10.1158/1535-7163.MCT-15-0076

Chicago Style (17th ed.) Citation

M, Hazar-Rethinam, et al. "RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell Carcinoma." Molecular Cancer Therapeutics 14, no. 8 (2015): 1939. https://doi.org/10.1158/1535-7163.MCT-15-0076.

MLA (9th ed.) Citation

M, Hazar-Rethinam, et al. "RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell Carcinoma." Molecular Cancer Therapeutics, vol. 14, no. 8, 2015, p. 1939, https://doi.org/10.1158/1535-7163.MCT-15-0076.